Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing